SK7799A3 - Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses - Google Patents

Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses Download PDF

Info

Publication number
SK7799A3
SK7799A3 SK77-99A SK7799A SK7799A3 SK 7799 A3 SK7799 A3 SK 7799A3 SK 7799 A SK7799 A SK 7799A SK 7799 A3 SK7799 A3 SK 7799A3
Authority
SK
Slovakia
Prior art keywords
ige
hsa
polypeptide
leu
glu
Prior art date
Application number
SK77-99A
Other languages
English (en)
Slovak (sk)
Inventor
Mary E Digan
Philip Lake
Hermann Gram
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK7799A3 publication Critical patent/SK7799A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70535Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SK77-99A 1996-07-26 1997-07-25 Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses SK7799A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69021696A 1996-07-26 1996-07-26
PCT/EP1997/004066 WO1998004718A1 (en) 1996-07-26 1997-07-25 Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses

Publications (1)

Publication Number Publication Date
SK7799A3 true SK7799A3 (en) 1999-07-12

Family

ID=24771594

Family Applications (1)

Application Number Title Priority Date Filing Date
SK77-99A SK7799A3 (en) 1996-07-26 1997-07-25 Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses

Country Status (27)

Country Link
EP (1) EP0917581B1 (de)
JP (1) JP3681402B2 (de)
KR (1) KR100502879B1 (de)
CN (1) CN1146664C (de)
AR (1) AR008077A1 (de)
AT (1) ATE383429T1 (de)
AU (1) AU722069B2 (de)
BR (1) BR9710605A (de)
CA (1) CA2261562C (de)
CO (1) CO4650184A1 (de)
CZ (1) CZ297634B6 (de)
DE (1) DE69738452T2 (de)
ES (1) ES2300114T3 (de)
ID (1) ID19420A (de)
IL (2) IL128094A0 (de)
MY (1) MY120425A (de)
NO (1) NO323611B1 (de)
NZ (1) NZ333908A (de)
PE (1) PE99498A1 (de)
PL (1) PL189415B1 (de)
PT (1) PT917581E (de)
RU (1) RU2209211C2 (de)
SK (1) SK7799A3 (de)
TR (1) TR199900155T2 (de)
TW (1) TW565571B (de)
WO (1) WO1998004718A1 (de)
ZA (1) ZA976666B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1056471A4 (de) * 1998-01-29 2001-05-30 Tanox Inc BEHANDLUNG ATOPISCHER DERMATITIS MIT IgE ANTAGONISTEN
CA2330527A1 (en) * 1998-06-15 1999-12-23 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
EP1208194A2 (de) * 1999-08-09 2002-05-29 Genaissance Pharmaceuticals, Inc. Isogene arzneimittel-ziele: polymorphismen des gens der immunglobulin e rezeptor i alpha untereinheit
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
DE10026998A1 (de) * 2000-05-31 2001-12-13 Fresenius Kabi De Gmbh Verfahren zur Herstellung einer kosmetischen Zusammensetzung, die humanes Serum Albumin umfasst, welches aus transgenen nicht-menschlichen Säugern erhalten wurde
UA93662C2 (uk) 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
DK2401383T3 (da) 2009-02-27 2013-12-16 Novartis Ag Fremgangsmåder til udvælgelse af eukaryote celler, som udtrykker et heterologt protein
WO2012169735A2 (ko) * 2011-06-07 2012-12-13 (주)네오팜 FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물
RU2506271C2 (ru) * 2011-06-22 2014-02-10 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД А2, СЕЛЕКТИВНО СВЯЗЫВАЮЩИЙ HSA, РЕКОМБИНАНТНАЯ ДНК pa2, КОДИРУЮЩАЯ HSA-СВЯЗЫВАЮЩУЮ ЧАСТЬ ПОЛИПЕПТИДА A2, ЕГО ПРОДУЦЕНТ - РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15-A2, СОДЕРЖАЩИЙ РЕКОМБИНАНТНУЮ ПЛАЗМИДНУЮ ДНК pQE 32-pa2, ОБЕСПЕЧИВАЮЩУЮ ПОЛУЧЕНИЕ ПОЛИПЕПТИДА A2 И ПРИМЕНЕНИЕ ПОЛИПЕПТИДА А2 ДЛЯ ДИАГНОСТИКИ МИКРОАЛЬБУМИНУРИИ И ВЫДЕЛЕНИЯ HSA ИЗ СЫВОРОТКИ КРОВИ
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
JP2018515073A (ja) * 2015-05-04 2018-06-14 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーLaboratoire Francais du Fractionnement et des Biotechnologies Fc融合タンパク質のトランスジェニック産生
EP3192806A1 (de) 2016-01-13 2017-07-19 Affiris AG Alpha-kette des hochaffinen ige-rezeptors (fceria)
JP7127859B2 (ja) * 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
BR112022000246A2 (pt) * 2019-07-08 2022-02-22 Gi Innovation Inc Dímero polipeptídico com elevado teor de ácido siálico, compreendendo o domínio extracelular da subunidade alfa do receptor fc de ige e composição farmacêutica compreendendo o mesmo
CN114302891A (zh) * 2019-07-08 2022-04-08 普罗根有限公司 新的il-10变体蛋白及其用途
CN111773392B (zh) * 2020-05-25 2023-04-07 河南省生物工程技术研究中心 一种人血白蛋白/寡核苷酸纳米颗粒及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962035A (en) * 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
CA2059842A1 (en) * 1991-02-11 1992-08-12 Richard A. Chizzonite Ige-receptor-antibodies

Also Published As

Publication number Publication date
JP3681402B2 (ja) 2005-08-10
CZ24699A3 (cs) 1999-04-14
IL128094A0 (en) 1999-11-30
CA2261562C (en) 2011-04-05
AU722069B2 (en) 2000-07-20
PL189415B1 (pl) 2005-08-31
ES2300114T3 (es) 2008-06-01
CN1229439A (zh) 1999-09-22
IL128094A (en) 2006-08-20
NO990328L (no) 1999-02-19
AU4202597A (en) 1998-02-20
EP0917581B1 (de) 2008-01-09
CA2261562A1 (en) 1998-02-05
EP0917581A1 (de) 1999-05-26
DE69738452D1 (de) 2008-02-21
WO1998004718A1 (en) 1998-02-05
ATE383429T1 (de) 2008-01-15
ID19420A (id) 1998-07-09
CO4650184A1 (es) 1998-09-03
KR100502879B1 (ko) 2005-07-25
JP2000516089A (ja) 2000-12-05
NO990328D0 (no) 1999-01-25
MY120425A (en) 2005-10-31
DE69738452T2 (de) 2008-12-24
HK1020352A1 (en) 2000-04-14
KR20000029563A (ko) 2000-05-25
NO323611B1 (no) 2007-06-18
TW565571B (en) 2003-12-11
PE99498A1 (es) 1999-01-21
ZA976666B (en) 1999-01-25
CN1146664C (zh) 2004-04-21
TR199900155T2 (xx) 2000-08-21
RU2209211C2 (ru) 2003-07-27
AR008077A1 (es) 1999-12-09
PT917581E (pt) 2008-04-11
NZ333908A (en) 1999-10-28
BR9710605A (pt) 1999-08-17
CZ297634B6 (cs) 2007-02-21
PL331356A1 (en) 1999-07-05

Similar Documents

Publication Publication Date Title
SK7799A3 (en) Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses
EP3248610B1 (de) Fgf21-mutanten und verwendungen davon
CN103328502A (zh) 治疗fgf21相关的病症的方法
EP2427207A2 (de) Fgf21-mutanten und ihre verwendungen
US6423512B1 (en) Fusion polypeptides
HK1020352B (en) Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses
HK40110187A (en) Fgf21 mutants and uses thereof
MXPA99000970A (en) Fusion polypeptides com0prising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses
HK1247134B (en) Fgf21 mutants and uses thereof
HK1168537B (en) Fgf21 mutants and uses thereof
HK1168537A (en) Fgf21 mutants and uses thereof